Aytu BioPharma Inc. held an Investor Day on January 20, 2026, in New York City, with both in-person and webcast participation. The event highlighted the commercial launch of EXXUA™ (gepirone) extended-release for major depressive disorder (MDD), outlining the company's focused launch strategy, sales force initiatives, and commitment to broad patient access. A replay of the event is available on the company’s investor relations website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1129218) on January 20, 2026, and is solely responsible for the information contained therein.
Comments